FDA 483 - Southern California Reproductive Center Medical Group PC - July 08, 2025

An FDA inspection of Southern California Reproductive Center Medical Group PC, a reproductive fertility center in Beverly Hills, CA, identified significant deficiencies in their HCT/P donor eligibility determinations. The firm was cited for determining donors eligible prior to receiving communicable disease testing results and for deeming donors eligible despite positive responses or unanswered questions on donor risk behavior assessments. These findings indicate a failure to ensure donor safety and compliance with screening protocols.